Ticagrelor Manufacturers

What is Ticagrelor?

Ticagrelor is a medication used to treat and/or prevent acute coronary syndrome, heart attack, myocardial infarction as well as atherothrombotic events. The supplier of these pharmaceutical substances markets it in the form of 60mg and 90mg tablets. The developer and sole manufacturer of this is AstraZeneca, which first acquired approval to market the drug in Europe in 2010, and in the U.S. in 2011. It has since then become approved in over 100 countries worldwide, including China, Japan, India, Brazil, and many others, as Brilinta in some countries and Brilique in others. Given that the patent for the drug is still valid, other manufacturers have yet to join the market with their generic or trade name formulations of the drug. Primary alternatives to tricagrelor are other ADP receptor inhibitor class drugs: cangrelor, clopidogrel, prasugrel and ticlopidine. The retail prices per 56 (90mg) tablets of these medicines fall into an approximate range of 60,00 EUR to 70,00 EUR. Pharmaceutical specialists are welcome to browse through offers of these tablets from it’s suppliers and distributors on our pharmaceutical marketplace, or else seek out further useful medical information about the medication online at the official Brilinta website. In persons who have had a cardiac arrest or who have an acute illness, it is being used to avoid a significant or life-threatening cardiac event, as well as death. It is often used to reduce the risk of stroke in persons who have had coronary stents implanted to treat ACS. It is a drug that is used to lower the risk of that first sudden cardiac arrest in persons who have cardiovascular disease. It's also used to help individuals experiencing a mild - to - moderate stroke or myocardial infarction reduce their chances of having an even more serious stroke.

How Does Ticagrelor Works?

It prevents platelets from clumping together and causing clots, which can lead to cardiovascular disease or stroke. Ticagrelor is an inhibitor of the P2Y12 channel. The P2Y12 transmitter binds to Gi2 and other Gi enzymes, which stop adenylyl cyclase from working. PI3K, Akt, Rap1b, and k streams are all activated by Gi-mediated transmission. Antagonism of the P2Y12 receptor reduces the development of occlusive thromboses, which can reduce the risk of myocardial infarction and ischemic stroke. Ticagrelor is available as a pill to be swallowed. It's commonly taken twice a day, with or without meals. Every day, take it at the same frequency. If you can't swallow it’s tablets whole, smash them and mix them with liquid. Consume the concoction right away, then replace with water, whisk, and drink it right away again. If you have a nasal cannula, your health practitioner will show you how to start preparing this medicine for administration through it. Ticagrelor will only help you control serious heart and lung issues if you take it regularly. Even if you feel fine, keep taking ticagrelor. There is a greater chance of having a heart attack or stroke if you stop using ticagrelor. If you have got a stent, you run an increased risk of a blood clot forming in the catheter if you quit taking inoculated too soon.

The Wholesale Price of Ticagrelor

Navigating Our Pharmaceutical Marketplace

Establishing Commercial Ties

Quality Assurance